Research programme: cannabinoids diagnostics and therapeutics - CellPoint/Vyripharm Biopharmaceuticals

Drug Profile

Research programme: cannabinoids diagnostics and therapeutics - CellPoint/Vyripharm Biopharmaceuticals

Alternative Names: 68Ga-N4-Endocannabinoid; 99mTc EC-OS2-DZ; 99mTc-N4-Endocannabinoid; 99mTc-N4-Tryptophan; 99mTc-N4-Tyrosine; EC-OS-Methotrexate; N4-Endocannabinoid

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CellPoint; Vyripharm Biopharmaceutical
  • Class Antiepileptic drugs; Cannabinoids; Diagnostic conjugates
  • Mechanism of Action Cannabinoid receptor agonists; Dopamine receptor agonists; Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epilepsy; Neurological disorders; Post-traumatic stress disorders

Most Recent Events

  • 26 Jul 2017 Preclinical trials in Epilepsy in USA (Transdermal) (CellPoint pipeline, July 2017)
  • 26 Jul 2017 Preclinical trials in Neurological disorders (Diagnosis) in USA (unspecified route) (CellPoint pipeline, July 2017)
  • 26 Jul 2017 Preclinical trials in Post-traumatic stress disorder in USA (Transdermal) (CellPoint pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top